Drug intelligence / Profile preview

BGB-108

Development stage: Unknown
Lead developer: BeiGene
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BGB-108 is an investigational PD-1 antagonist antibody developed by BeiGene for use in immuno-oncology. It functions by blocking the programmed cell death protein 1 (PD-1) receptor to enhance T-cell mediated anti-tumor immune responses, similar to other PD-1 inhibitors like pembrolizumab and nivolumab. It is being explored in combination therapies, particularly with anti-AXL antibody-drug conjugates, for potential treatment of various solid tumors, though specific primary indications remain under investigation in early-stage development.[3]

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on BGB-108.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BGB-108.

Explore the full profile